Skip to content
    TC

    Tekla Capital Management

    Boston, Massachusetts, United StatesFounded 1986
    www.teklacapital.comLinkedIn
    HealthcareBiotech & Life Sciences

    Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts, acting as the investment adviser for four closed-end funds that invest predominantly in public and private healthcare companies. Its advisory business was acquired by abrdn Inc. in October 2023.

    55% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $85.9M (across 15 rounds with reported amounts).

    Find people at Tekla Capital Management on Goldilocks AI

    Portfolio

    19

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    0

    Team

    HS

    Henry Skinner

    Managing Director

    JH

    Julian Harrison

    Managing Director

    CR

    Christian Richard

    Partner

    CA

    Chris Abbott

    Investment Director

    DO

    Daniel Omstead

    CEO

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    20 investments
    CompanyRoundAmountDate
    Quell Therapeutics logoQuell TherapeuticsSeries B$156MNov 2021
    Arbor Biotechnologies logoArbor BiotechnologiesSeries B$215MNov 2021
    HiberCell logoHiberCellSeries B$67.4MMay 2021
    Quell Therapeutics logoQuell TherapeuticsSeries B$156MJan 2021
    PPriothera Ltd.Series A—Oct 2020
    Hotspot Therapeutics logoHotspot TherapeuticsSeries B$65MMay 2020
    Arkuda Therapeutics logoArkuda TherapeuticsSeries A$44MNov 2019
    AAmphivena TherapeuticsSeries C$62MSep 2019
    Galera logoGaleraSeries C—Sep 2018
    TTherachonDebt—Aug 2018
    SSutro BioPharma, Inc.Series E$85.4MJul 2018
    CCurasenSeries A$54.5MJan 2018
    Milestone Pharmaceuticals logoMilestone PharmaceuticalsSeries C$55MAug 2017
    Insightra Medical, Inc logoInsightra Medical, IncSeries C—Jan 2014
    ReCode Therapeutics logoReCode TherapeuticsSeries B$50M—
    Caribou Biosciences logoCaribou BiosciencesSeries C$115M—
    Sutro Biopharma logoSutro BiopharmaSeries E$85.4M—
    ImmuneID logoImmuneIDSeries A$50M—
    Dynacure logoDynacureSeries C——
    IIlluminOss MedicalSeries C$28M—

    Top Co-Investors

    Ridgeback Capital4 shared
    SV Health Investors4 shared
    Alta Partners4 shared
    Pfizer Ventures3 shared
    Surveyor Capital3 shared
    ARCH Venture Partners3 shared
    AJU IB Investment3 shared
    Amgen Ventures3 shared
    Pappas Capital3 shared
    Atlas Venture2 shared
    Solasta Ventures2 shared
    Sofinnova Partners2 shared
    OrbiMed2 shared
    MPM Capital2 shared
    Adage Capital Management2 shared
    Jeito Capital2 shared
    AlbionVC2 shared
    British Patient Capital2 shared
    Celgene2 shared
    Eventide Asset Management2 shared

    Last updated: 8 September 2026